| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President Of R&D, Therapeutics | See Remarks
1 company
Akinsanya Karen is a President Of R&D, Therapeutics at Schrodinger, Inc.. Recent SEC Form 4 filings include 0 buys and 25 sells.
Estimated insider holdings value: $377K based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 14, 2025 | SDGR Schrodinger, Inc. | President Of R&D, Therapeutics | Sale+OE | 16,723 | $25.09 | $419,570.35 | -22.2% | -20.3% | -57.2% | |
| Oct 15, 2021 | SDGR Schrodinger, Inc. | See Remarks | Sale+OE | 1,393 | $55.75 | $77,659.75 | -100% | -46.4% | -60.4% | |
| Sep 15, 2021 | SDGR Schrodinger, Inc. | See Remarks | Sale+OE | 1,394 | $61.13 | $85,215.22 | -100% | -42.1% | -52.5% | |
| Aug 16, 2021 | SDGR Schrodinger, Inc. | See Remarks | Sale+OE | 37,738 | $57.75 | $2,179,314.08 | -70.2% | -20.8% | -47.7% | |
| Jun 8, 2021 | SDGR Schrodinger, Inc. | See Remarks | Sale+OE | 16,721 | $75.37 | $1,260,206.20 | -95.4% | -16.4% | -63.5% | |
| Dec 18, 2020 | SDGR Schrodinger, Inc. | See Remarks | Sale+OE | 13,377 | $80.00 | $1,070,160.00 | -100% | - | - | |
| Aug 17, 2020 | SDGR Schrodinger, Inc. | See Remarks | Sale+OE | 3,344 | $68.04 | $227,519.59 | -86.2% | - | - | |
| Aug 12, 2020 | SDGR Schrodinger, Inc. | See Remarks | Sale+OE | 20,065 | $67.32 | $1,350,729.97 | -21.1% | - | - |